Galectin Therapeutics Inc. (GALT)
GALTNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$3.38
-0.0800 (-2.31%) today
Closed, Nov 10, 4:00 PM ET
- Market cap
- $341.63m
- P/E
- –
- EPS, last 4 quarters
- $-0.4300
- Dividend yield
- –
- Day range
- –
- 52-week range
- $2.03 to $7.13
- Average volume
- 257.9k
- Previous close
- $3.46
Analysts
1 coveringBuy1 buy, 0 hold, 0 sell
Targets a year out average $11.00, +225.4% from here
Earnings
next estimate $-0.0500Next report Nov 13, 2026
Sep 2025
-18.2%
Dec 2025
+20.0%
Mar 2026
-33.3%
Jun 2026
-55.6%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$4.20m | -$3.37m | -$4.08m | -$3.98m |
| Net income | -$8.18m | -$5.50m | -$5.05m | -$9.11m |
News
8 latest- Galectin Loss Widens In Q2; Plans Phase 3 MASH Trial For Q3 2026 RTTNews · Aug 19, 2026
- Top Biotech Gainers: QTTB Sends Strong SIGNAL; AMWL And SI In Focus RTTNews · Jul 13, 2026
- Top Biotech Gainers: PLSM Inks Virtual Maternity Care Deal, ICCM Turns Heads, SLN Hits New High RTTNews · Jun 24, 2026
- GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASHZacks · Jun 24, 2026
- Top Biotech Gainers: BOLD Begins Anew, MNPR NDA Filing On Track, GALT Soars On FDA Alignment RTTNews · Jun 23, 2026
- Galectin Aligns With FDA Feedback To Advance Belapectin In MASH Cirrhosis And Portal Hypertension RTTNews · Jun 23, 2026
- Galectin Rises After Publishing Positive Phase 2b Data For Belapectin In Treating MASH Cirrhosis RTTNews · May 11, 2026
- Galectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock?Zacks · Apr 3, 2026
The company
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin's lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis and portal hypertension, the most advanced form of MASH-related fibrosis. Liver cirrhosis is one of the most pressing medical needs and a significant drug development opportunity. Additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- galectintherapeutics.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.